Poly-(ADP Ribose) Polymerase (PARP) inhibitors (talazoparib, olaparib) has been recently approved for the treatment of breast and ovarian cancers with BRCA1/2 mutations, and several others drugs inhibiting or modulating DNA repair pathways are currently in clinical development for cancer therapy (Table 5). Here, BRCA1 is linked to ovarian carcinoma.